Abstract Details

A Phase I Dose-Escalating Study of AAV1-Gamma-Sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
Muscle Disease/Neuromuscular Junction
(-)
001
Authors/Disclosures
Olivier Benveniste, MD, PhD (Hôpital Pitié-Salpêtrière) No disclosure on file
Oana M. Dumitrascu, MD, FAAN (Mayo Clinic) Dr. Dumitrascu has nothing to disclose.
Faycal Hentati, MD No disclosure on file
Bruno Eymard, MD No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file